(secondQuint)A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer.

 This is 12-week, open-label study of abiraterone acetate in at least 50 patients with metastatic castration-resistant prostate cancer.

 The primary endpoint is total testosterone at pharmacokinetic steady-state.

 Additional secondary endpoints include safety assessments, PSA and pharmacokinetic measurements.

 A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer@highlight

The purpose of this study is to evaluate the serum testosterone levels in patients with Metastatic Castration-Resistant Prostate Cancer on SoluMatrix cent Abiraterone Acetate as Compared to Abiraterone Acetate